Cytodyn Inc (CYDY)

[Borel Fields]

NEJM latest re: HCQ as post-exposure prophylaxis: No significant benefit.

800 people identified as having high exposure to a confirmed case were randomized to receive either HCQ or placebo. Outcome = covid test or symptoms at 14 days. Favorable, but non-significant trend for HCQ, which also had 2.5 times as many side effects.

"The incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was -2.4 percentage points (95% confidence interval, -7.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), but no serious adverse reactions were reported."

https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?query=TOC